Klebsiella (e.g., Klebsiella Pneumoniae, Etc.) Patents (Class 424/259.1)
-
Patent number: 10251946Abstract: The invention provides methods of modulating an immune system in a vertebrate host for the therapeutic or prophylactic treatment of infection by a first microbial pathogen in a target tissue, comprising administration at an administration site of an effective amount of an antigenic formulation comprising antigenic determinants specific for a second heterologous microbial pathogen.Type: GrantFiled: May 1, 2015Date of Patent: April 9, 2019Assignee: Qu Biologics Inc.Inventors: Harold David Gunn, Salim Dhanji, David W. Mullins
-
Publication number: 20140093536Abstract: The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of a protein isolated from bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions.Type: ApplicationFiled: July 30, 2013Publication date: April 3, 2014Inventors: Jiri Pillich, John C. Balcarek
-
Publication number: 20140037716Abstract: The present invention relates to immunogenic compositions for modulating the immune system, comprising a therapeutically effective quantity of two or more immuno-active antigenic agents with pathogen-associated molecular patterns (PAMPs) and/or danger-associated molecular patterns (DAMPs) and one or more physiologically acceptable carriers, excipients, diluents or solvents. The immunogenic compositions according to the present invention are used for producing medicaments for preventing and/or treating, and for preventing and/or treating infectious diseases, auto-immune diseases, allergic diseases, inflammation, arthritis, inflammatory diseases, transplant rejection, affections caused by vascular disorders, diseases caused by haemorrhagic or ischaemic cardiovascular accidents, ischaemia, heart attack and haemorrhagia leading to tissue destruction, heart, kidney, respiratory or liver insufficiency, cancer, malign and benign tumours and neoplasia.Type: ApplicationFiled: March 19, 2012Publication date: February 6, 2014Inventor: Alexandre Eduardo Nowill
-
Patent number: 8637052Abstract: The present invention relates to an isolated nucleic acid molecule encoding an antigen, a vector comprising such nucleic acid molecule and a host cell comprising such vector. Furthermore, the invention provides antigens from Klebsiella species, fragments and variants thereof, a process for producing such antigens, and a process for producing cells expressing such antigens. Moreover, the present invention provides antibodies binding to such antigen, hybridoma cells producing such antibodies, methods for producing such antibodies, a pharmaceutical composition comprising such nucleic acid molecule, antigen, vector or antibody, the use of such nucleic acid molecule, antigen, vector or antibody for the preparation of a pharmaceutical composition, methods for identifying an antagonist capable of binding such antigen or of inhibiting the interaction activity of such antigen, methods for diagnosis or for treatment or prevention of an infection.Type: GrantFiled: July 6, 2012Date of Patent: January 28, 2014Assignee: Valneva Austria GmbHInventors: Sharmila Bakshi, Thomas Cipps, Markus Hanner, Jutta Pikalo, Christina Satke, Eszter Nagy, Urban Lundberg, Dagmar Zierer, Andreas Meinke, Birgit Noiges, Ulrike Stierschneider, Alexander Von Gabain
-
Publication number: 20130251748Abstract: The present invention relates a method for vaccinating a mammal to produce an antibody against Enterobacteriaceae infection caused by Klebsiella pneumoniae, Salmonella typhi, or E. coli in central nervous system and/or peripheral blood circulation, which comprises administering an effective amount of an OmpK36/homologues or its derivatives to the mammal.Type: ApplicationFiled: July 10, 2012Publication date: September 26, 2013Applicant: NATIONAL DEFENSE MEDICAL CENTERInventors: Leung-Kei Siu, Feng-Yee Chang, Yung-Chung Lin, Chang-Phone Fung, Yip-Mei Liu, Jiun-Han Chen, Yu-Kuo Tsai, Pele Choi-Sing Chong, Chih-Hsiang Leng, Shih-Jen Liu, Hsin-Wei Chen
-
Publication number: 20130202616Abstract: The present invention provides vaccine and pharmaceutical compositions for treating or preventing bacterial inventions. The vaccine compositions of the invention include a carbapenemase such as a serine carbapenemase, a metallo-?-lactamase or an immunogenic fragment thereof. The pharmaceutical compositions include an anti-carbapenemase antibody or fragment thereof. Also provided are methods for treating and preventing a bacterial infection using the vaccine and pharmaceutical compositions of the invention. The invention further provides antibody conjugates that include an antibody or fragment thereof conjugated to a siderophore or an analog thereof.Type: ApplicationFiled: January 24, 2013Publication date: August 8, 2013Applicant: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: Brad J. Spellberg, Lin Lin
-
Patent number: 8361441Abstract: The present invention provides a method for the treatment and/or prevention of bacterial infection caused by Enterobacteriaceae bacteria in central nervous system and/or peripheral blood circulation in a mammal by administering effective amount of outer membrane protein A (OmpA) or its derivatives to a mammal. Also provided are a method for vaccinating a mammal to produce an antibody against bacterial infection caused by Enterobacteriaceae family in central nervous system and/or peripheral blood circulation and a method of detecting or diagnosing bacterial infections caused by Enterobacteriaceae family in central nervous system and/or peripheral blood circulation in a mammal. An antibody and a kit on the basis of the vaccinating method and detecting/diagnosing method are also provided.Type: GrantFiled: September 29, 2009Date of Patent: January 29, 2013Assignee: Taipei Medical UniversityInventors: Yi-Yuan Yang, Hsueh-Hsia Wu, Sy-Jye Leu, Neng-Yao Shih, I-Jen Huang, Wen-Shyang Hsieh, Ko-Jiunn Liu, Shih-Yi Huang, Yung-Luen Shih, Chi-Hsin Lee, Yuan-Soon Ho, Shih-Lan Hsu
-
Publication number: 20120222142Abstract: The present application relates to a composition including gut flora-derived extracellular vesicles, and to an animal disease model using same. In addition, the present application relates to a method for using the gut flora-derived extracellular vesicles to efficiently search for a candidate drug which may prevent or treat diseases that occur due to gut flora-derived extracellular vesicles, and to a vaccine which can efficiently prevent or treat infections caused by gut flora or diseases that occur due to gut flora-derived extracellular vesicles. Further, the development of diagnostic technology to discover, using the gut flora-derived extracellular vesicles of the present application, the etiology of diseases that occur due to gut flora-derived extracellular vesicles, can be achieved.Type: ApplicationFiled: July 20, 2010Publication date: August 30, 2012Applicant: AEON MEDIX INC.Inventors: Yoon Keun Kim, Yong Song Gho, Kyoung Su Park, Bok Sil Hong, Ji Hyun Kim, You Sun Kim, Won Hee Lee, Jung Wook Kim, Dae-Kyum Kim
-
Patent number: 8252575Abstract: A newly isolated lytic bacteriophage specifically against Klebsiella pneumoniae, deposited at DSMZ-Deutsche Sammlung von Mikroorganismen and Zellkulturen with deposit number (DSM 24329), shows broad host ranges and lytic effects on K. pneumoniae isolated from Taiwan under either in vivo or in vitro models.Type: GrantFiled: January 7, 2011Date of Patent: August 28, 2012Assignee: I-Shou UniversityInventors: Nina Tsao, Chih-Hsin Hung, Chih-Feng Kuo
-
Patent number: 8236326Abstract: The present invention relates to isolated nucleic acid molecules which encode an antigen, a vector which comprises such nucleic acid molecule, and a host cell comprising such vector. Furthermore, the invention provides antigens from a Klebsiella species, as well as fragments and variants thereof, a process for producing such antigens, and a process for producing a cell, which expresses such antigen. Moreover, the present invention provides antibodies binding to such antigen, a hybridoma cell producing such antibodies, methods for producing such antibodies, a pharmaceutical composition comprising such nucleic acid molecule, antigen, vector or antibody, the use of such nucleic acid molecule, antigen, vector or antibody for the preparation of a pharmaceutical composition, methods for identifying an antagonist capable of binding such antigen or of reducing or inhibiting the interaction activity of such antigen, methods for diagnosing an infection and methods for the treatment or prevention of an infection.Type: GrantFiled: April 29, 2008Date of Patent: August 7, 2012Assignee: Intercell AGInventors: Sharmila Bakshi, Thomas Cipps, Markus Hanner, Jutta Pikalo, Christina Satke, Eszter Nagy, Urban Lundberg, Dagmar Zierer, Andreas Meinke, Birgit Noiges, Ulrike Stierschneider, Alexander von Gabain
-
Publication number: 20120100178Abstract: The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of a protein isolated from bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions.Type: ApplicationFiled: October 24, 2011Publication date: April 26, 2012Inventors: Jiri Pillich, John C. Balcarek
-
Publication number: 20120045430Abstract: Various nucleic acid-based matrixes are provided, comprising nucleic acid monomers as building blocks, as well as nucleic acids encoding proteins, so as to produce novel biomaterials. The nucleic acids are used to form dendrimers that are useful as supports, vectors, carriers or delivery vehicles for a variety of compounds in biomedical and biotechnological applications. In particular, the macromolecules may be used for the delivery of drugs, genetic material, imaging components or other functional molecule to which they can be conjugated. An additional feature of the macromolecules is their ability to be targeted for certain organs, tumors, or types of tissues. Methods of utilizing such biomaterials include delivery of functional molecules to cells.Type: ApplicationFiled: August 15, 2011Publication date: February 23, 2012Inventors: Dan Luo, Yougen Li
-
Patent number: 8034359Abstract: The invention provides in part methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated. The formulations of the invention thereby facilitate activation of a treatment response to a cancer in a particular tissue or organ. The compositions may for example include killed or attenuated microbial pathogens, and may be administered at sites distant from the cancer, for example the skin. In some embodiments, microbial species of endogenous flora that are known to cause infection in the relevant organ or tissue may be used in the formulation of the antigenic compositions. In alternative embodiments, exogenous microbial pathogens that are known to cause infection in the relevant organ or tissue may be used in the formulation of the antigenic compositions.Type: GrantFiled: September 19, 2008Date of Patent: October 11, 2011Assignee: Qu Biologics Inc.Inventor: Harold David Gunn
-
Publication number: 20110200616Abstract: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.Type: ApplicationFiled: April 21, 2011Publication date: August 18, 2011Applicant: Epitopix, LLCInventors: Daryll A. Emery, Darren E. Straub, Donavan E. Zammert, Gayla K. Kallevig
-
Publication number: 20110150931Abstract: Booster immunization can lead to rapid induction of protective immunity against pathogens (e.g. ?7 days after the booster dose). This rapid response means that booster immunization can be used at short notice prior to an event that might require an activated immune response. For instance, a subject can be primed at a young age against a pathogen that typically affects more elderly subjects under specific circumstances such that, when the subject is older, the immune response can be mobilized rapidly if those specific circumstances are expected. An example would be to prime a subject against infections that are typically acquired nosocomially and then, soon before a scheduled hospital appointment, to boost their immune response so that they enter hospital in an immune-alert state.Type: ApplicationFiled: June 25, 2009Publication date: June 23, 2011Inventors: Giuseppe Del Giudice, Rino Rappuoli
-
Publication number: 20110104207Abstract: The present invention relates to compounds which inhibit bacterial gyrase and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals. The present invention also relates to a method for preparing these compounds.Type: ApplicationFiled: April 16, 2010Publication date: May 5, 2011Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Paul CHARIFSON, David DEININGER, Joseph DRUMM, Anne-Laure GRILLOT, Yusheng LIAO, Patricia OLIVER-SHAFFER, Dean STAMOS
-
Publication number: 20100285064Abstract: The present invention provides a Withania somnifera fraction rich in withanolides and a vaccine comprising a “Withania somnifera fraction” as an adjuvant.Type: ApplicationFiled: May 5, 2010Publication date: November 11, 2010Applicant: SERUM INSTITUTE OF INDIA LTD.Inventors: Suresh Sakharam Jadhav, Bhushan Patwardhan, Manish Gautam
-
Publication number: 20100272758Abstract: The present invention provides non-toxic Gram-negative bacteria. In particular, the present invention provides viable Gram-negative bacteria (e.g., E. coli) substantially lacking lipopolysaccharide (LPS, endotoxin) within the outer membrane. The present invention further provides methods of generating viable non-toxic Gram-negative bacteria and uses thereof. The present invention also provides compositions and methods for inducing immune responses and for researching and developing therapeutic agents.Type: ApplicationFiled: January 19, 2007Publication date: October 28, 2010Applicant: Regents of the University of MichiganInventors: Ronald Wesley Woodard, Timothy Charles Meredith, Parag Aggarwal
-
Patent number: 7807139Abstract: The present invention provides a method for the treatment and/or prevention of bacterial infection caused by Klebsiella pneumoniae and other gram-negative bacteria in central nervous system and/or peripheral blood circulation in a mammal by administering effective amount of outer membrane protein A (OmpA) or its derivatives to a mammal. Also provided are a method for vaccinating a mammal to produce an antibody against bacterial infection caused by Enterobacteriaceae family in central nervous system and/or peripheral blood circulation and a method of detecting or diagnosing bacterial infections caused by Enterobacteriaceae family in central nervous system and/or peripheral blood circulation in a mammal.Type: GrantFiled: January 23, 2009Date of Patent: October 5, 2010Assignee: Taipei Medical UniversityInventors: Yi-Yuan Yang, Hsueh-Hsia Wu, Sy-Jye Leu, Neng-Yao Shih, I-Jen Huang, Ching-Yu Lin, Wen-Shyang Hsieh, Ko-Jiunn Liu, Shih-Yi Huang, Yueh-Lun Lee, Chi-Hsin Lee, Yuan-Soon Ho, Shih-Lan Hsu
-
Patent number: 7790183Abstract: This invention relates to a method for coating a medical device comprising the steps of applying to at least a portion of the surface of said medical device, an antimicrobial coating layer and a non-pathogenic bacterial coating layer, wherein the antimicrobial and non-pathogenic bacterial coating layers inhibit the growth of pathogenic bacterial and fungal organisms. The non-pathogenic bacterium used in the bacterial coating layer is resistant to the antimicrobial agent. Furthermore, the non-pathogenic bacterium layer includes at least one of the following: viable whole cells, non-viable whole cells, or cellular structures or extracts. The antimicrobial agent and non-pathogenic bacterium are used to develop a kit comprising these compositions in one container or in separate containers. The kit is used to coat a catheter prior to implantation in a mammal.Type: GrantFiled: February 26, 2004Date of Patent: September 7, 2010Assignee: Baylor College of MedicineInventors: Rabih O. Darouiche, Richard Hull
-
Publication number: 20100215679Abstract: The disclosure provides an antigenic composition useful for immunization against tularemia. The disclosure provides a method for producing a vaccine for preventing tularemia in humans and animals, a new vaccine against tularemia in humans and animals, and a new approach to producing vaccines against tularemia.Type: ApplicationFiled: October 22, 2007Publication date: August 26, 2010Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Marcus A. Horwitz, Qingmei Jia, Bai-Yu L. Clemens, Daniel Clemens
-
Publication number: 20100158941Abstract: The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions.Type: ApplicationFiled: December 17, 2009Publication date: June 24, 2010Inventors: Jiri Pillich, John Balcarek
-
Publication number: 20100129408Abstract: The present invention relates to a Klebsiella pneumoniae gene-deleted mutant and its producing methods. The main objective of this invention is to construct a Klebsiella pneumoniae tonB deletion mutant used as an immunogenically effective amount of a live attenuated vaccine against the community-acquired pyogenic liver abscess, where the tonB gene was deleted. The tonB deletion mutant maintained the structure of the capsular polysaccharide on cell membrane surface, and induced no disease on the mouse after injection. In addition, the tonB deletion mutants induced the immunity against pyogenic liver abscess caused by Klebsiella pneumoniae.Type: ApplicationFiled: May 1, 2009Publication date: May 27, 2010Applicant: NATIONAL TAIWAN UNIVERSITYInventors: Jin-Town Wang, Pei-Fang Hsieh, Tzu-Lung Lin, Cha-Ze Lee, Shih-Feng Tsai
-
Publication number: 20100055129Abstract: Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response.Type: ApplicationFiled: August 28, 2009Publication date: March 4, 2010Applicant: TAIGA BIOTECHNOLOGIES, INC.Inventors: Yosef Refaeli, Brian Curtis Turner
-
Patent number: 7608247Abstract: The present invention provides a method for the treatment and/or prevention of bacterial infection in central nervous system and/or peripheral blood circulation in a mammal by administering effective amount of outer membrane protein A (OmpA) or its derivatives to a mammal. Also provided is an antibody binding to OmpA that can assay OmpA levels in a biological sample and detect or diagnose bacterial infection in central nervous system and/or peripheral blood circulation.Type: GrantFiled: March 11, 2008Date of Patent: October 27, 2009Assignee: Taipei Medical UniversityInventors: Yi-Yuan Yang, Hsueh-Hsia Wu, Sy-Jye Leu, I-Jen Huang, Neng-Yao Shih, Ko-Jiunn Liu, Mei-Ru Chen, Wen-Shyang Hsieh, Chi-Hsin Lee
-
Publication number: 20090214531Abstract: The invention features methods and compositions for treating or preventing Gram-negative bacterial infections.Type: ApplicationFiled: January 29, 2007Publication date: August 27, 2009Inventors: John Mekalanos, Stefan Pukatzki, Joseph Mougous
-
Patent number: 7408044Abstract: The invention relates to an adjuvant product which is intended to improve the activity of a molecule when administered to a host, characterized in that it comprises at least one part of the P40 protein of Klebsiella pneumoniae or a protein having at least 80% homology with the P40 protein of Klebsiella pneumoniae. The invention also relates to nucleotide sequences which encode these peptides or proteins and to the use of these sequences as a medicament. More particularly, such DNA sequences can be used in compositions which are intended for immunization by the intramuscular or intradermal route.Type: GrantFiled: April 1, 2004Date of Patent: August 5, 2008Assignee: Pierre Fabre MedicamentInventors: Hans Binz, Thierry Baussant, Jean-François Haeuw, Thien Ngoc Nguyen
-
Publication number: 20080171002Abstract: Phosphorylated glucomannan polysaccharide compositions are shown to effectively enhance healthy immune function. Dosage forms including pills, sprays, functional foods and cosmetics may achieve this benefit while being essentially free of storage protein from nongerminated seeds of Ricinus communis.Type: ApplicationFiled: July 20, 2007Publication date: July 17, 2008Applicant: GOURMETCEUTICALS, LLCInventors: Jose Antonio Matji Tuduri, Antonio F. Guerrero Gomez-Pamo, Jose Luis Alonso Lebrero, Garrett Lindemann, Manuel Lopez Cabrera, Pedro Majano Rodriguez, Ricardo Moreno Otero, Diego Serrano Gomez, Angel Corbi Lopez, Samuel Martin Vilchez
-
Patent number: 7371393Abstract: The present invention provides methods for reducing shedding in an animal. Generally, the method includes administcriirn to an animal a composition including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter.Type: GrantFiled: March 22, 2006Date of Patent: May 13, 2008Assignee: Epitopix, LLCInventors: Daryll A. Emery, Darren E. Straub
-
Patent number: 7341732Abstract: The present invention provides methods for treating mastitis in a milk producing animal. The methods include administering compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter.Type: GrantFiled: April 22, 2004Date of Patent: March 11, 2008Assignee: Epitopix, LLCInventors: Daryll A. Emery, Darren E. Straub
-
Patent number: 7160549Abstract: The present invention provides methods for making compositions including siderophore receptor polypeptides and porins from gram negative microbes. The methods include providing a gram negative microbe, disrupting the microbe, solubilizing the disrupted microbe, and isolating the polypeptides.Type: GrantFiled: April 22, 2004Date of Patent: January 9, 2007Assignee: Epitopix, LLCInventors: Daryll A. Emery, Darren E. Straub, Donavan E. Zammert, Gayla K. Kallevig
-
Patent number: 7125696Abstract: A invention concerns a novel method for preparing a polypeptide soluble in an aqueous solvent in the absence of detergent, and polypeptides obtainable by said method. The invention also concerns the use of said polypeptides, in particular for preparing medicines or vaccines, for fighting against bacterial and viral infections or cancers.Type: GrantFiled: January 4, 2001Date of Patent: October 24, 2006Assignee: Pierre Fabre MedicamentInventors: Thierry Baussant, Pascale Jeannin, Yves Delneste, François Lawny, Jean-Yves Bonnefoy
-
Patent number: 7090853Abstract: An adjuvant composition comprising noscapine and its derivatives, for use in the treatment of tumors, cancer, as an adjuvant for vaccines.Type: GrantFiled: November 6, 2002Date of Patent: August 15, 2006Assignee: Emory UniversityInventors: Judith Kapp, Yong Ke
-
Patent number: 7033591Abstract: The invention concerns the use of a membrane fraction of gram-negative bacteria, in particular Klebsiella pnemoniae for preparing a pharmaceutical composition that is immunostimulant and/or capable of inducing an antitumoral immune response, designed in particular for treating and preventing cancers. The invention further comprises methods for preparing said membrane factions and pharmaceutical compositions containing them, in particular combined with anticancer compounds.Type: GrantFiled: March 15, 2000Date of Patent: April 25, 2006Assignee: Pierre Fabre MedicamentInventors: Christine Libon, Nathalie Corvaia, Alain Beck, Jean-Yves Bonnefoy
-
Patent number: 7018636Abstract: A vaccine, effective in inducing the production of antibodies with which to immunize a second subject passively against infection by Gram-negative bacteria and LPS-mediated pathology, comprises a non-covalent polyvalent complex formed between purified, detoxified LPS derived from E. coli and purified outer membrane protein derived from N. meningitidis. The same vaccine will also actively immunize a host subject against Gram-negative bacterial infections and LPS-mediated pathology. Meningococcal infections are included among those Gram-negative bacterial infections protected against by the vaccine.Type: GrantFiled: June 30, 1997Date of Patent: March 28, 2006Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Apurba Bhattacharjee, Alan Cross, Jerald Sadoff, Wendell Zollinger
-
Patent number: 6913753Abstract: The invention features incapacitated whole cell bacterial immunogenic compositions produced by infecting a bacterium with Lys minus bacteriophage, which are deficient in the lysin protein. Lys minus bacteriophage retain activity in infection of its appropriate bacterial host, destruction of the bacterial genome, and replication, which are sufficient to inhibit bacterial growth and replication. The resulting, Lys minus-infected bacterium is provided in a state of bacteriostasis, and is not capable of replicating further (e.g., is “incapacitated”). The incapacitated bacterium can then be used as to elicit an immune response for prophylactic and/or therapeutic purposes. The invention thus also features incapacitated bacteria formulated appropriately for use in immunogenic compositions for eliciting an immune response, e.g., for production of antibodies in a non-human host or in a whole cell bacterial vaccine.Type: GrantFiled: September 27, 2002Date of Patent: July 5, 2005Assignee: Gangagen, Inc.Inventors: Janakiraman Ramachandran, Sriram Padmanabhan, Bharathi Sriram
-
Patent number: 6905691Abstract: The invention relates to a vaccine comprising a bacterium attenuated by a non-reverting mutation in a gene encoding a protein which promotes folding of extracytoplasmic proteins. Such mutations were initially identified as being useful in vaccines from a bank of randomly inserted, transposon mutants in which attenuation was determined as a reduction in virulence of the organism in the mouse model of infection. Site directed mutation of the gene results in a strain which shows at least 4 logs of attenuation when delivered both orally and intravenously. Animals vaccinated with such a strain are protected against subsequent challenge with the parent wild type strain. Finally, heterologous antigens such as the non-toxic and protective, binding domain from tetanus toxin, fragment C, can be delivered via the mucosal immune system using such strains of bacteria. This results in the induction of a fully protective immune response to subsequent challenge with native tetanus toxin.Type: GrantFiled: June 9, 2000Date of Patent: June 14, 2005Assignee: Celltech Pharma Europe LimitedInventors: Steven Neville Chatfield, Gordon Dougan, Mark Sydenham
-
Patent number: 6780420Abstract: The invention relates to an adjuvant product which is intended to improve the activity of a molecule when administered to a host, characterized in that it comprises at least one part of the P40 protein of Klebsiella pneumoniae or a protein having at least 80% homology with the P40 protein of Klebsiella pneumoniae. The invention also relates to nucleotide sequences which encode these peptides or proteins and to the use of these sequences as a medicament. More particularly, such DNA sequences can be used in compositions which are intended for immunization by the intramuscular or intradermal route.Type: GrantFiled: October 5, 2000Date of Patent: August 24, 2004Assignee: Pierre Fabre MedicamentInventors: Hans Binz, Thierry Baussant, Jean-François Haeuw, Thien Nguyen Ngoc
-
Publication number: 20040097464Abstract: The present invention relates to a mixture of non-sulfated fucose-based oligosaccharides, characterized in that it comprises oligosaccharides of less than 13 saccharide units, comprising at least one fucose unit in a non-reducing end position, and in that at least it is capable of being obtained by means of a process that comprises at least one step of degradation of a polysaccharide from a microorganism of the gender Klebsiella pneumoiae subsp. pneumoniae. This new mixture presents significant activities on different components of the skin, providing a clearly visible anti-aging result, specially by an excellent thickening of the skin.Type: ApplicationFiled: June 23, 2003Publication date: May 20, 2004Inventors: Ladislas Robert, Alexandre Michel Robert, Catherine Sylvie Robert, Jean-Luc Gesztesi
-
Patent number: 6632431Abstract: The present invention relates to an anti-idiotypic antibody or antigen-binding fragment against FimH adhesin of uropathogenic Type I-fimbriated Escherichia coli and an immunizing composition containing such an anti-idiotypic antibody or antigen-binding fragment thereof as an active immunizing component. The present invention also relates to a method for stimulating and enhancing the production of antibodies which recognize and bind to FimH of uropathogenic Type-I-fimbriated Escherichia coli, but not to FimH of non-uropathogenic Type I-fimbriated Escherichia coli.Type: GrantFiled: May 10, 2001Date of Patent: October 14, 2003Assignee: New York UniversityInventor: Xue-Ru Wu
-
Publication number: 20030152594Abstract: The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions.Type: ApplicationFiled: February 13, 2003Publication date: August 14, 2003Inventors: Jiri Pillich, John Balcarek
-
Patent number: 6423320Abstract: A polysaccharide and fragments thereof derived from Klebsiella oxytoca or Klebsiella pneumonia inhibit the IgE antibody production and response and, therefore, are useful in the prophylaxis and/or treatment of type I allergy-related diseases.Type: GrantFiled: August 19, 1998Date of Patent: July 23, 2002Assignee: Tayca CorporationInventors: Hitoshi Oomori, Yoichi Ooiso, Ryosuke Sugihara
-
Publication number: 20020041885Abstract: A polysaccharide and fragments thereof derived from Klebsiella oxytoca or Klebsiella pneumonia inhibits the IgE antibody production and response in vivo and therefore, they are useful in the prophylaxis and treatment type I allergy-related diseaseType: ApplicationFiled: August 19, 1998Publication date: April 11, 2002Applicant: MILLEN, WHITE, ZELANO, BRANIGAN, P.C.Inventors: HITOSHI OOMORI, YOICHI OOISO, RYOSUKE SUGIHARA
-
Patent number: 6197929Abstract: The invention relates to an adjuvant product which is intended to improve the activity of a molecule when administered to a host, characterized in that it comprises at least one part of the P40 protein of Klebsiella pneumoniae or a protein having at least 80% homology with the P40 protein of Klebsiella pneumoniae. The invention also relates to nucleotide sequences which encode these peptides or proteins and to the use of these sequences as a medicament. More particularly, such DNA sequences can be used in compositions which are intended for immunization by the intramuscular or intradermal route.Type: GrantFiled: August 11, 1997Date of Patent: March 6, 2001Inventors: Hans Binz, Thierry Baussant, Jean-François Haeuw, Thien Nguyen Ngoc